ReviewMethodist DeBakey cardiovascular journal
Critical limb ischemia: cell and molecular therapies for limb salvage.
Review in Methodist DeBakey cardiovascular journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus.Journal of cardiovascular translational research · 2021Trial
- Molecular Mediated Angiogenesis and Vasculogenesis Networks.International journal of molecular sciences · 2025Article
- Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome.International journal of environmental research and public health · 2022Article
- Role of Lipid-Lowering Therapy in Peripheral Artery Disease.Journal of clinical medicine · 2022Review
- Assessment of endothelial colony forming cells delivery routes in a murine model of critical limb threatening ischemia using an optimized cell tracking approach.Stem cell research & therapy · 2022Article
- Efficient generation of endothelial cells from induced pluripotent stem cells derived from a patient with peripheral arterial disease.Cell and tissue research · 2022Article
- Collateral Arteriogenesis Involves a Sympathetic Denervation That Is Associated With Abnormal α-Adrenergic Signaling and a Transient Loss of Vascular Tone.Frontiers in cardiovascular medicine · 2022Article
- Cell Therapy for Critical Limb Ischemia: Advantages, Limitations, and New Perspectives for Treatment of Patients with Critical Diabetic Vasculopathy.Current diabetes reports · 2021Review
- REX-001, a BM-MNC Enriched Solution, Induces Revascularization of Ischemic Tissues in a Murine Model of Chronic Limb-Threatening Ischemia.Frontiers in cell and developmental biology · 2020Article
- Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101.Scientific reports · 2016Article
- A review of the pathophysiology and potential biomarkers for peripheral artery disease.International journal of molecular sciences · 2015Review
- Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.Annals of medicine · 2014Review
- Polymerase δ-interacting protein 2 promotes postischemic neovascularization of the mouse hindlimb.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing interest in developing new limb salvage therapies for patients with severe peripheral artery disease who have no alternative to amputation. Cell and gene therapy studies are showing promise in controlling pain and minor ulceration in patients with significant critical limb ischemia. Among cardiovascular cell and molecular therapy programs, The Methodist Hospital is one of the leading centers in both gene and cell therapy for critical limb ischemia. Randomized controlled trials continue to be performed, and these experimental therapies will move from research to pharmacy within the decade. In conjunction with aggressive medical and surgical management, these emergent therapies may help patients with critical limb ischemia avoid a major amputation and are one of the foundations of any advanced limb salvage program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.